Sex differences in K+-evoked striatal dopamine output from superfused striatal tissue fragments of reserpine-treated CD-1 mice

J Neuroendocrinol. 2007 Sep;19(9):725-31. doi: 10.1111/j.1365-2826.2007.01581.x.

Abstract

Reserpine inhibits vesicular monoamine transporter-2 (VMAT-2) function and thereby impairs vesicular dopamine (DA) storage within nerve terminals. The present report compared the effects of reserpine treatment upon the striatal dopaminergic system in male and female mice as a means to assess potential sex differences in VMAT-2/DA storage function. After treatment with reserpine, male mice showed significantly greater striatal DA concentrations and K+ -evoked DA output from the striatum compared to females. By contrast, no statistically significant sex differences were observed in methamphetamine-evoked DA output in reserpine-treated mice. These results demonstrate a clear sex difference in the striatal dopaminergic responses to reserpine and suggest that females possess a more active VMAT-2/DA storage capacity, as indicated by the greater degree of deficits observed when VMAT-2/DA storage function is inhibited by reserpine. Such findings have important implications for understanding some of the bases for sex differences in neurotoxicity and neurodegeneration of the nigrostriatal dopaminergic system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Uptake Inhibitors / metabolism*
  • Animals
  • Corpus Striatum / anatomy & histology
  • Corpus Striatum / metabolism*
  • Dopamine / metabolism*
  • Dopamine Agents / metabolism
  • Female
  • Male
  • Methamphetamine / metabolism
  • Mice
  • Potassium / metabolism*
  • Reserpine / metabolism*
  • Sex Factors
  • Tissue Culture Techniques
  • Vesicular Monoamine Transport Proteins / metabolism

Substances

  • Adrenergic Uptake Inhibitors
  • Dopamine Agents
  • Slc18a2 protein, mouse
  • Vesicular Monoamine Transport Proteins
  • Methamphetamine
  • Reserpine
  • Potassium
  • Dopamine